Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

Key Terms

catheter ablation medical

Catheter ablation is a minimally invasive medical procedure in which a thin, flexible tube is threaded into the heart to destroy tiny areas of tissue that cause abnormal heart rhythms, typically using heat or freezing. Investors watch it because growing use or improved success rates can shift demand for specialized medical devices, hospital procedures and follow-up care, alter treatment costs, and compete with drug or implantable alternatives — like repairing a faulty circuit to restore reliable performance.

cardiac arrhythmias medical

Cardiac arrhythmias are conditions in which the heart beats too fast, too slow, or with an irregular rhythm rather than its normal steady pulse. They matter to investors because arrhythmias drive demand for drugs, monitoring tools, implanted devices and hospital care, and because trial results, approvals or safety concerns related to arrhythmia treatments can quickly change a company’s revenue outlook—think of it as a steering issue in a car that affects repair and replacement markets.

electrophysiology medical

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

ce-mark regulatory

A CE mark is a label placed on products to show they meet European Union safety, health and environmental rules, allowing legal sale across the EU/EEA. Think of it as a passport or safety sticker that signals regulators have checked essential standards; for investors it matters because it affects a product’s market access, potential sales, and regulatory risk—lack of a CE mark can block entry to a large market and reduce expected revenue.

fda approvals regulatory

FDA approvals are formal permissions granted by the U.S. Food and Drug Administration allowing a drug, medical device, or related product to be marketed and sold for a specific use after safety and effectiveness have been evaluated. For investors, an FDA approval is like a green light that can unlock sales, reduce regulatory uncertainty, and increase a product’s commercial value, while also signaling lower near-term regulatory risk compared with unapproved alternatives.

pulsed field ablation medical

Pulsed field ablation is a heart procedure that uses very short, high-voltage electrical pulses to selectively disrupt abnormal heart tissue that causes irregular rhythms, rather than heating or freezing it. For investors, it matters because this approach can shorten procedure times, reduce damage to nearby structures, and potentially lower complication rates compared with traditional thermal methods, which can affect device adoption, hospital costs, and market demand for treatment tools.

transcatheter aortic valve replacement medical

A minimally invasive procedure that replaces a damaged aortic heart valve by guiding a folded replacement valve to the heart through a thin tube (catheter) inserted in a blood vessel, avoiding the need for open‑chest surgery. It matters to investors because it shapes demand for medical devices, hospital services and reimbursements, impacts patient recovery times and complication rates, and can materially influence sales, margins and regulatory risk for device makers and healthcare providers — like swapping a worn door using a narrow hallway instead of tearing down a wall.

tavr medical

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that replaces a failing aortic heart valve by delivering a new valve through a blood vessel instead of opening the chest. It matters to investors because TAVR expands who can be treated, shortens hospital stays and recovery, and shapes revenue, regulatory risk and reimbursement for medical device makers, hospitals and insurers—similar to how a popular new product can reshape an industry’s market and costs.

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and Compensation Committee.

Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company’s cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic’s Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Ablation, Structural Heart and Aortic, Coronary and Renal Denervation, Peripheral Vascular and Cardiac Surgery businesses. As a portfolio leader he was responsible for optimizing enterprise performance through capital allocation, talent development, strategic investments, and cross-portfolio collaboration.

During his career, Mr. Salmon built extensive expertise across electrophysiology (“EP”) therapies, including surgical and catheter-based ablation. He also led several strategic initiatives central to Medtronic’s growth in the EP and ablation markets, including the acquisition of Affera, the asset acquisition of Acutus’ transeptal crossing technology, and the successful CE-Mark and FDA approvals for the Pulse Select and Sphere 9 pulsed field ablation catheters, followed by their global commercialization.

“Adagio’s proprietary ultralow temperature ablation technology has the potential to represent a truly best-in-class innovation addressing an important unmet need for patients suffering from ventricular arrythmias,” said Sean Salmon. “I believe the technology and its clinical results show significant potential to address the shortcomings of current treatments being used in the ventricle and to give physicians a unique, purpose-built solution for their patients. I am excited to be part of the future of Adagio and look forward to collaborating with the Board and management.”

Earlier at Medtronic, Mr. Salmon served as President of Coronary & Structural Heart, where he led all aspects of the business, including Clinical, Regulatory, Research & Development, Marketing, Sales, Operations, Supply Chain, Quality, Health Economics & Reimbursement, Business Development, Finance, and Strategy. Under his leadership, Medtronic successfully entered the highly competitive drug-eluting stent market and expanded the company’s transcatheter aortic valve replacement (TAVR) franchise through successive innovation cycles, broadening treatment indications and accelerating global adoption.

Mr. Salmon also previously served as Executive Vice President and President of the Medtronic Diabetes Operating Unit, where he led a multi-year portfolio transformation. Earlier in his career, he held management roles at C.R. Bard, Johnson & Johnson, SurgiVision, and EuroRSCG Life. He holds an MBA from the Kellogg School of Management at Northwestern University and a BS in Applied Physiology from Boston University.

“Sean is an exceptional operator with a proven ability to build, scale, and lead high-performance medical technology organizations in competitive, clinically driven markets,” said Todd Usen, Chief Executive Officer of Adagio Medical. “His broad EP experience—including leadership across ablation technologies—paired with his deep physician relationships and experience commercializing breakthrough platforms will be invaluable to Adagio as we advance our proprietary ultralow temperature ablation technologies.”

Mr. Salmon’s appointment expands Adagio Medical’s Board with a highly respected industry veteran whose expertise aligns directly with the Company’s strategic priorities, including commercial planning and execution, pipeline innovation, and disciplined operating oversight.

About Adagio Medical Holdings, Inc.

Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.

About FULCRUM VT

FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.

Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning Adagio’s strategy, future operations, prospects, plans and objectives of management and the potential for FDA approval and commercialization of Adagio’s product candidates. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Adagio’s business are described in detail in Adagio’s Securities and Exchange Commission (“SEC”) filings, including in its Annual Report on Form 10-K for the full-year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Adagio makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Adagio disclaims any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251211410117/en/

Debbie Kaster

Chief Financial Officer and Chief Business Officer

dkaster@adagiomedical.com

Source: Adagio Medical Holdings, Inc